JPWO2023078881A5 - - Google Patents
Info
- Publication number
- JPWO2023078881A5 JPWO2023078881A5 JP2024521120A JP2024521120A JPWO2023078881A5 JP WO2023078881 A5 JPWO2023078881 A5 JP WO2023078881A5 JP 2024521120 A JP2024521120 A JP 2024521120A JP 2024521120 A JP2024521120 A JP 2024521120A JP WO2023078881 A5 JPWO2023078881 A5 JP WO2023078881A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- degrader
- compound
- cancer
- mek
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21206336 | 2021-11-04 | ||
| EP21206336.6 | 2021-11-04 | ||
| PCT/EP2022/080475 WO2023078881A1 (en) | 2021-11-04 | 2022-11-02 | Novel use of quinazolinone compound for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024539852A JP2024539852A (ja) | 2024-10-31 |
| JP2024539852A5 JP2024539852A5 (https=) | 2025-11-11 |
| JPWO2023078881A5 true JPWO2023078881A5 (https=) | 2025-11-11 |
Family
ID=78516703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024521120A Pending JP2024539852A (ja) | 2021-11-04 | 2022-11-02 | がんの治療のためのキナゾリノン化合物の新規使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240366605A1 (https=) |
| EP (1) | EP4426305A1 (https=) |
| JP (1) | JP2024539852A (https=) |
| KR (1) | KR20240105382A (https=) |
| CN (1) | CN118201615A (https=) |
| AU (1) | AU2022383040A1 (https=) |
| CA (1) | CA3230652A1 (https=) |
| IL (1) | IL312171A (https=) |
| MX (1) | MX2024005107A (https=) |
| TW (1) | TW202333707A (https=) |
| WO (1) | WO2023078881A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7834721B2 (ja) | 2020-08-28 | 2026-03-24 | アルビナス・オペレーションズ・インコーポレイテッド | 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法 |
| WO2022261250A1 (en) | 2021-06-08 | 2022-12-15 | C4 Therapeutics, Inc. | Therapeutics for the degradation of mutant braf |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| CN120265291A (zh) * | 2022-11-18 | 2025-07-04 | 豪夫迈·罗氏有限公司 | 喹唑啉酮化合物的新用途和制剂 |
| CN120359214A (zh) * | 2022-12-15 | 2025-07-22 | 豪夫迈·罗氏有限公司 | 用于癌症治疗的组合疗法 |
| WO2025261943A1 (en) * | 2024-06-18 | 2025-12-26 | F. Hoffmann-La Roche Ag | Anti-cancer combinations comprising mosperafenib and folfox or folfiri |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| HRP20110498T1 (hr) | 2005-10-07 | 2011-08-31 | Exelixis | Azetidini kao inhibitori mek za liječenje proliferativnih bolesti |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| CN105899493B (zh) | 2014-01-17 | 2019-03-29 | 诺华股份有限公司 | 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物 |
| JP6523303B2 (ja) | 2014-01-17 | 2019-05-29 | ノバルティス アーゲー | Ｓｈｐ２の活性を阻害するための１−ピリダジン／トリアジン−３−イル−ピペラジン／ピペリジン／ピロリジン誘導体およびその組成物 |
| MX2020003579A (es) | 2017-10-12 | 2020-07-22 | Revolution Medicines Inc | Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos. |
| TWI817018B (zh) * | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和失調症之化合物 |
| PL4073065T3 (pl) | 2019-12-10 | 2025-05-19 | F. Hoffmann-La Roche Ag | Nowe pochodne metylochinazolinonu |
| BR112023025916A2 (pt) * | 2021-06-09 | 2024-02-27 | Chugai Pharmaceutical Co Ltd | Combinação de um inibidor de braf e um inibidor de mek, uso de uma combinação, método para o tratamento ou profilaxia de câncer, composições farmacêuticas e invenção |
| AU2022289684A1 (en) * | 2021-06-09 | 2023-10-05 | F. Hoffmann-La Roche Ag | Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer |
-
2022
- 2022-11-02 AU AU2022383040A patent/AU2022383040A1/en active Pending
- 2022-11-02 WO PCT/EP2022/080475 patent/WO2023078881A1/en not_active Ceased
- 2022-11-02 MX MX2024005107A patent/MX2024005107A/es unknown
- 2022-11-02 EP EP22814296.4A patent/EP4426305A1/en active Pending
- 2022-11-02 CN CN202280073254.9A patent/CN118201615A/zh active Pending
- 2022-11-02 KR KR1020247014717A patent/KR20240105382A/ko active Pending
- 2022-11-02 IL IL312171A patent/IL312171A/en unknown
- 2022-11-02 JP JP2024521120A patent/JP2024539852A/ja active Pending
- 2022-11-02 CA CA3230652A patent/CA3230652A1/en active Pending
- 2022-11-03 TW TW111142082A patent/TW202333707A/zh unknown
-
2024
- 2024-05-03 US US18/653,975 patent/US20240366605A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025065346A5 (ja) | 組み合わせ物 | |
| Fukuoka et al. | A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. | |
| Moertel et al. | Mitomycin C therapy in advanced gastrointestinal cancer | |
| JP7169297B2 (ja) | 再発膠芽腫（ｒｇｂｍ）の治療方法 | |
| JP2010043114A (ja) | 腫瘍転移および癌の治療 | |
| Hedayat et al. | Selumetinib: a selective MEK1 inhibitor for solid tumor treatment | |
| WO2016204193A1 (ja) | 抗がん剤 | |
| JPWO2022269525A5 (https=) | ||
| JP2002544231A5 (https=) | ||
| CN117157106A (zh) | 药物在治疗肿瘤疾病中的应用 | |
| JP2019524713A5 (https=) | ||
| Lucke-Wold et al. | Focus on current and emerging treatment options for glioma: A comprehensive review | |
| KR20210019116A (ko) | 카복시아미도트리아졸 오로테이트를 사용하여 화학치료제 및 표적화된 약물에 대해 내성을 획득한 암을 치료하기 위한 방법 및 조성물 | |
| CN106075450A (zh) | 用于树突状细胞癌症疫苗的小分子增强剂 | |
| Ariel | Therapeutic effects of hydroxyurea. Experience with 118 patients with inoperable solid tumors | |
| JP2007511499A (ja) | コンビネーション | |
| JPWO2023078881A5 (https=) | ||
| Pazdur et al. | Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma. | |
| Fukuoka et al. | Clinical studies of irinotecan alone and in combination with cisplatin | |
| JPWO2019196764A5 (https=) | ||
| JPH1045589A (ja) | テモゾロミドによる改良されたガンの処置 | |
| Qu et al. | Oral fruquintinib combined with tegafur-gimeracil-oteracil potassium for advanced colorectal cancer to obtain longer progression-free survival: A case report | |
| RU2024114532A (ru) | Новое применение хиназолинонового соединения для лечения рака | |
| Balakan et al. | Long-term survival in metastatic malignant melanoma: ipilimumab followed by vemurafenib in a patient with brain metastasis | |
| JPWO2023035611A5 (https=) |